BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ariosa Diagnostics, Inc. Completes Clinical Study of Harmony™ Prenatal Test on a General Pregnant Patient Population


7/25/2012 10:02:02 AM

SAN JOSE, Calif., July 24, 2012 /PRNewswire/ -- Ariosa Diagnostics, Inc., a molecular diagnostics company, announced today the completion of the first clinical study to evaluate non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) in a general population of pregnant women. The patients of this study were from a single large obstetrical practice over a specified period of time and represent an average-risk population for that center. The study's significance is that it evaluates the Harmony Prenatal Test in a population primarily containing pregnant women at low risk for chromosomal abnormalities. Detailed results from this blinded, independent study are being prepared for submission to a peer-reviewed journal.

"The completion of this average-risk study demonstrates our ongoing commitment to validate the effectiveness of the Harmony Prenatal Test in pregnant women," said Ken Song, MD, chief executive officer for Ariosa Diagnostics. "We look forward to collaborating with all stakeholders in the healthcare system to ensure broad access to NIPT, which we believe will lead to better prenatal care."

This new study from Ariosa adds to the robust clinical study portfolio supporting the Harmony test, which to date, includes four major publications. The first study published in January 2012 in Prenatal Diagnosis was a proof-of-concept study on Ariosa's directed cfDNA approach to accurately detect fetal trisomies. Following this, two studies a blinded study in a high-risk population of pregnant women and an independent study in a similar high-risk population exclusively from the first trimester were published jointly in the American Journal of Obstetrics and Gynecology. More recently, the largest NIPT cohort study comprising both high-risk and average-risk women in either their first or second trimester was published in the American Journal of Obstetrics and Gynecology. The completion of the current general population study further supports the clinical benefit of NIPT to be used broadly.

"These studies clearly demonstrate the accuracy of the Harmony test," said Tom Musci, MD, maternal fetal medicine specialist and vice president of medical affairs and clinical development for Ariosa Diagnostics. "NIPT provides a much needed option for prenatal testing of common fetal trisomies, and physicians should be empowered with this technology to determine how best to manage their pregnant patients."

Ariosa is also pleased to announce that its laboratory has received accreditation from the College of American Pathologists (CAP). CAP accreditation is based on rigorous standards and is internationally recognized as a program that helps laboratories achieve the highest standards of excellence to positively impact patient care.

About Ariosa Diagnostics
Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariosadx.com.

SOURCE Ariosa Diagnostics, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->